4-(2-丁氧基乙氧基)苯甲醛 | 63735-44-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-(2-丁氧基乙氧基)苯甲醛
• 英文名称: 4-(2-butoxyethoxy)benzaldehyde
• 英文别名: 4-butoxyethoxy benzaldehyde
• CAS: 63735-44-4
• 化学式: C₁₃H₁₈O₃
• 分子量: 222.284
• InChiKey: LXFUAPGMBNAONH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  氯仿 、 4-(2-丁氧基乙氧基)苯甲醛 在 苄基三乙基氯化铵 、 sodium hydroxide 、 水 、 盐酸 作用下， 以 氯仿 、 水 为溶剂， 反应 6.0h， 以95%的产率得到4-butoxyethoxy-α-hydroxy benzeneacetic acid
  参考文献：
  名称：

  [EN] ALPHA-HYDROXY-BENZENEACETIC ACID DERIVATIVES, AND COMPOUNDS HAVING TWO 5-MEMBERED LACTONE RINGS FUSED TO CENTRAL CYCLOHEXA-1,4-DIENE NUCLEUS BASED UPON THE SAME, AND USES OF THE COMPOUNDS
  [FR] DERIVES D'ACIDE ALPHA-HYDROXY-BENZENEACETIQUE ET COMPOSES A BASE DE CEUX-CI COMPRENANT DEUX CYCLES LACTONE A 5 ELEMENTS FUSIONNES A UN NOYAU CYCLOHEXA-1,4-DIENE CENTRAL, ET UTILISATION DESDITS COMPOSES

  摘要：

  本发明提供了一种如规范中定义的具有以下结构的α-羟基苯乙酸衍生物，该衍生物是合成具有两个5-成员内酯环融合到中心环己-1,4-二烯核的化合物所必需的前体，并提供了一种简便制备该衍生物的方法。根据本发明的制备过程，可以在高纯度和产率下轻松制备α-羟基苯乙酸衍生物，而无需使用有毒材料或产生有毒副产品。通过使用这种α-羟基苯乙酸衍生物合成的一些新化合物，在合成纤维材料（如涤纶纤维及其与其他纤维的混合物，特别是微纤维）具有优异的色牢度、染料固定率和均匀性能，还可以用作塑料树脂、颜色调节剂、颜色滤光片等的着色剂。

  公开号：

  WO2005028409A1
• 作为产物：
  描述：

  2-丁氧乙基对甲苯磺酸酯 、 对羟基苯甲醛 在 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以74%的产率得到4-(2-丁氧基乙氧基)苯甲醛
  参考文献：
  名称：

  Synthesis and biological evaluation of novel 4-hydroxybenzaldehyde derivatives as tyrosinase inhibitors

  摘要：

  A series of novel 4-hydroxybenzaldehyde derivatives were synthesized and their inhibitory effects on the diphenolase activity of mushroom tyrosinase were investigated. Most of target compounds had more potent inhibitory activities than the parent compound 4-hydroxybenzaldehyde (IC50 = 1.22 mM). Interestingly, compound 3c bearing a dimethoxyl phosphate was found to be the most potent inhibitor with IC50 value of 0.059 mM. The inhibition kinetics analyzed by Lineweaver-Burk plots revealed that compound 3c was a non-competitive inhibitor (K-I = 0.0368 mM). In particular, compound 3c showed no side effects at dose of 1600 mg/kg in mice. These results suggested that such compounds might be served as lead compounds for further designing new potential tyrosinase inhibitors. (C) 2009 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2009.11.007

文献信息

• Rational Design and Synthesis of 4-O-Substituted Phenylmethylenethiosemicarbazones as Novel Tyrosinase Inhibitors
  作者：Wei Yi、Rihui Cao、Zhiyong Chen、Liang Yu、Huan Wen、Qin Yan、Lin Ma、Huacan Song

  DOI：10.1248/cpb.58.752

  日期：——

  In continuing our program aimed to search for tyrosinase inhibitors, a series of novel 4-O-substituted phenylmethylenethiosemicarbazones were rational designed, synthesized and their inhibitory effects on the diphenolase activity of mushroom tyrosinase were also evaluated. A fair number of compounds were found to have significant tyrosinase inhibitiory activity. Particularly, the IC50 values of compounds 3a—g, 3j and 3s were of the same magnitude as tropolone, one of the best tyrosinase inhibitors known so far. Furthermore, the structure–activity relationships of these compounds were also investigated. All these data suggested that these molecules might be utilized for the development of new candidate for the treatment of dermatological disorders, and further development of such compounds may be of interest.

  在我们继续进行寻找酪氨酸酶抑制剂的项目中，合理设计并合成了一系列新型的4-O取代苯甲烯硫脲衍生物，同时评估了它们对蘑菇酪氨酸酶二酚酶活性的抑制效果。发现相当多的化合物具有显著的酪氨酸酶抑制活性。特别是化合物3a—g、3j和3s的IC50值与已知的最佳酪氨酸酶抑制剂之一的特罗泊酮相当。此外，这些化合物的结构—活性关系也进行了研究。所有这些数据表明，这些分子可能被用于开发治疗皮肤疾病的新候选药物，而且对这些化合物的进一步开发可能会引起兴趣。
• Cyclic polypeptide with antibiotic activity and a process for preparation thereof
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0729974A1

  公开（公告）日：1996-09-04

  A polypeptide compound of the following general formula : whereinR1 is acyl group, R2 is acyloxy, R3 is hydrogen and R4 is hydrogen and a pharmaceutically acceptable salt thereof, a process for its preparation and pharmaceutical compositions comprising it. The invention relates also to use of the compound for the manufacture of a medicament for treating or preventing infectious diseases.

  以下是通用式的多肽化合物： 其中，R1是酰基，R2是酰氧基，R3是氢，R4是氢，以及其药学上可接受的盐，制备该化合物的方法以及包含它的制药组合物。本发明还涉及使用该化合物制造治疗或预防传染病的药物。
• Liquid crystal compounds having ether tail moiety
  申请人：Polaroid Corporation

  公开号：US05132041A1

  公开（公告）日：1992-07-21

  Disclosed are smetic liquid crystal compounds exhibiting ferroelectric behavior and having the formula R.sup.1 --OR.sup.2).sub.a O--R.sup.3).sub.b Z--R* wherein R.sup.1 is alkyl or alkoxyalkyl, R.sup.2 and R.sup.3 are each alkylene, a is an integer of at least one, b is zero or one, R* is an optically active group containing an asymmetric center and --Z-- is an organic divalent core radical having parallel or coaxially extending bonds at the terminal ends thereof, the core radical having an axial ratio of at least two and being characterized by an essentially rigid and flat molecular structure. Presence of the ether-interrupted hydrocarbon tail moiety at the terminal end of the compounds provides a lowering in observed temperatures of phase transition.

  公开了一种展现铁电行为的液晶化合物，其化学式为R.sup.1 --OR.sup.2).sub.a O--R.sup.3).sub.b Z--R*，其中R.sup.1是烷基或烷氧基烷基，R.sup.2和R.sup.3分别是亚烷基，a是至少为1的整数，b为零或一，R*是含有不对称中心的光学活性基团，而--Z--是具有平行或同轴延伸的键的有机二价核心基团，该核心基团具有至少2的轴向比，并且具有基本刚性和平面分子结构。化合物的末端存在醚断裂的烃尾基，可降低相变观察温度。
• Pharmaceutical composition against Pneumocystis carinii
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0486011A2

  公开（公告）日：1992-05-20

  Use of a polypeptide compound of the formula : wherein R¹ is hydrogen or acyl group, R² is hydroxy or acyloxy, R³ is hydrogen, hydroxy or hydroxysulfonyloxy, R⁴ is hydrogen or carbamoyl, and R⁵ and R⁶ are each hydrogen or hydroxy, with proviso that (i) R² is acyloxy, when R³ is hydrogen, and (ii) R⁵ is hydrogen, when R⁶ is hydrogen, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the prevention and/or the treatment of Pneumocystis carinii infection.

  使用式 ： 其中 R¹ 是氢或酰基 R² 是羟基或酰氧基、 R³ 是氢、羟基或羟基磺酰氧基、 R⁴ 是氢或氨基甲酰基，以及 R⁵ 和 R⁶ 均为氢或羟基、 但条件是 (i) 当 R³ 为氢时，R² 为酰氧基，以及 (ii) 当 R⁵ 是氢时，R⁶ 是氢、 或其药学上可接受的盐，用于制备预防和/或治疗卡氏肺囊虫感染的药物。
• MOLECULAR PROBE PRECURSOR FOR PANCREATIC ISLET IMAGING AND USE OF SAME
  申请人：Kyoto University

  公开号：EP2407455A1

  公开（公告）日：2012-01-18

  A precursor of a molecular probe for imaging of pancreatic islets is a compound expressed as the following formula (I): wherein -V-X represents a substituent on a benzene ring, V represents a bond, R1, or OR1, R1 represents a C1-C6 alkylene group, R2 represents H (hydrogen atom), a C1-C6 alkyl group, a C7-C10 aralkyl group, or a protecting group, X represents a OMs group, a OTs group, a OTf group, Br (bromine atom), or I (iodine atom), and carbon marked with * is an asymmetric carbon atom.

  用于胰岛成像的分子探针的前体是下式 (I) 所表示的化合物： 其中 -V-X 代表苯环上的取代基，V 代表键、R1 或 OR1，R1 代表 C1-C6 亚烷基，R2 代表 H（氢原子）、C1-C6 烷基、C7-C10 芳烷基或保护基，X 代表 OMs 基、OTs 基、OTf 基、Br（溴原子）或 I（碘原子），标有 * 的碳是不对称碳原子。